-
公开(公告)号：EP3686187A1
公开(公告)日：2020-07-29
申请号：EP20160567.2
申请日：2016-08-02
发明人： DAS, Sanjib , GHARAT, Laxmikant, Atmaram , HARDE, Rajendra, Laxman , SHELKE, Sandeep, Yadunath , PARDESHI, Shailesh, Ramesh , THOMAS, Abraham , KHAIRATKAR-JOSHI, Neelima , SHAH, Daisy, Manish , BAJPAI, Malini
IPC分类号： C07D231/12 , C07D401/04 , C07D403/04 , C07D239/26 , C07D239/36 , C07D239/42 , C07D413/04 , C07D413/12 , C07D417/12 , C07D213/40 , A61K31/506 , A61P37/00
摘要： The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring B, L, R 1 , R 2 , R 3 , R 4 , R 5 , R a , R b , n, m, p and q are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
-
公开(公告)号：EP3619209A1
公开(公告)日：2020-03-11
申请号：EP18727437.8
申请日：2018-05-04
发明人： KUMAR, Sukeerthi , CHAUDHARI, Sachin Sundarlal , GHARAT, Laxmikant Atmaram , KHAIRATKAR-JOSHI, Neelima , SHAH, Daisy Manish , MUKHOPADHYAY, Indranil , THOMAS, Abraham
IPC分类号： C07D471/04 , C07D491/052 , C07D495/04 , C07D498/04 , C07D513/04 , A61P11/00 , A61P35/00 , A61K31/437 , A61K31/5377 , A61K31/444 , A61K31/496 , A61K31/4545
-
公开(公告)号：EP3517104A1
公开(公告)日：2019-07-31
申请号：EP19159387.0
申请日：2015-07-31
发明人： DHUPPAD, Ulhas , CHAUDHARI, Sunil , RAJURKAR, Suresh , JAIN, Nilesh , DHATRAK, Chandrakant , KASLIWAL, Alkesh
IPC分类号： A61K9/51 , A61K31/4196 , A61K9/20 , A61K9/48
摘要： The present invention relates to a nanoparticulate formulation comprising a microsomal prostaglandin E synthases-1 ("mPGES-1") inhibitor. Particularly, the present invention relates to a nanoparticulate formulation comprising an mPGES-1 inhibitor and one or more surface stabilizers; a process for preparing such formulation; and its use in treating pain and inflammation in a subject.
-
公开(公告)号：EP3174535B1
公开(公告)日：2019-02-27
申请号：EP15754023.8
申请日：2015-07-31
发明人： DHUPPAD, Ulhas , CHAUDHARI, Sunil , RAJURKAR, Suresh , JAIN, Nilesh , DHATRAK, Chandrakant , KASLIWAL, Alkesh
IPC分类号： A61K9/51 , A61K31/4196 , A61K9/20 , A61K9/48
-
公开(公告)号：EP2941302B1
公开(公告)日：2018-08-01
申请号：EP13811986.2
申请日：2013-12-23
IPC分类号： A61P37/00 , A61K39/395 , C07K16/28
CPC分类号： C07K16/2878 , A61K39/3955 , A61K47/6849 , A61K2039/505 , C07K16/2875 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
-
公开(公告)号：EP3341357A1
公开(公告)日：2018-07-04
申请号：EP16840923.3
申请日：2016-08-26
发明人： DAS, Sanjib , GHARAT, Laxmikant Atmaram , HARDE, Rajendra Laxman , SHELKE, Dnyaneshwar Eknath , PARDESHI, Shailesh Ramesh , THOMAS, Abraham , KHAIRATKAR-JOSHI, Neelima , SHAH, Daisy Manish , BAJPAI, Malini
IPC分类号： C07C311/16 , A61K31/167 , A61P35/00
CPC分类号： C07C237/42 , A61P11/06 , A61P11/08 , A61P11/14 , A61P17/06 , C07B2200/07 , C07C2601/02 , C07C2601/16
摘要： The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Ra, Rb, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.
-
公开(公告)号：EP3176185A1
公开(公告)日：2017-06-07
申请号：EP16206413.3
申请日：2014-11-04
发明人： Blein, Stanislas , Ollier, Romain , Skegro, Darko , Hou, Samuel
CPC分类号： C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
摘要翻译： 本发明描述了新的与CD3和疾病相关抗原结合的异源二聚体免疫球蛋白或其片段。 这些异二聚体免疫球蛋白已经被工程化以在表达过程中促进异二聚体的形成并且可以使用蛋白A差异纯化技术被高度纯化。
-
公开(公告)号：EP2900696A1
公开(公告)日：2015-08-05
申请号：EP13766540.2
申请日：2013-09-25
CPC分类号： C07K16/468 , B01D15/3809 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/567 , C07K2317/622
摘要： The present invention describes novel hetero-dimeric immunoglobulinvariants or fragments thereof, which have reduced or eliminated binding to Protein A, Protein G or both Protein A and Protein G. Also encompassed in the present invention are methods for the selective purification of hetero-dimeric immunoglobulins or fragments thereof using Protein A and Protein G.
-
9.发明公开ANTI-TRKA ANTIBODIES WITH ENHANCED INHIBITORY PROPERTIES AND DERIVATIVES THEREOF 有权人类抗逆转录酶抗逆转录酶氨基酸取代基
公开(公告)号：EP2859019A2
公开(公告)日：2015-04-15
申请号：EP13742750.6
申请日：2013-06-07
发明人： BLEIN, Stanislas , OLLIER, Romain , SKEGRO, Darko
IPC分类号： C07K16/28 , A61P29/00 , A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to antibodies directed against TrkA receptor and their uses, including humanized anti-TrkA antibodies. More specifically, the present invention relates to humanized anti-TrkA antibodies with enhanced inhibitory properties comprising a heavy chain variable region, a light chain, variable region, a human light chain constant region and a variant human IgG4 heavy chain constant region which exhibit altered exchange properties.
摘要翻译： 本发明涉及针对TrkA受体的抗体及其用途，包括人源化抗-TrkA抗体。 更具体地，本发明涉及具有增强的抑制性质的人源化抗-TrkA抗体，其包含重链可变区，轻链，可变区，人轻链恒定区和变异的人IgG4重链恒定区，其表现出改变的交换 属性。
-
10.发明公开PHARMACEUTICAL COMPOSITION COMPRISING A TRPA1 ANTAGONIST AND A STEROID 审中-公开药剂师ZUSAMMENSETZUNG MIT EINEM TRPA1-ANTAGONIST UND EINEM STEROID
公开(公告)号：EP2736513A1
公开(公告)日：2014-06-04
申请号：EP12748055.6
申请日：2012-07-23
发明人： KHAIRATKAR-JOSHI, Neelima , KULKARNI, Abhay , WALE, Dinesh Pradeep , KADAM, Anil Hari , BHOSALE, Vikram
IPC分类号： A61K31/505 , A61K31/56 , A61K31/573 , A61P11/00
CPC分类号： A61K31/519 , A61K9/0053 , A61K31/505 , A61K31/517 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： The present patent application relates to a pharmaceutical composition comprising a transient receptor potential ankyrin-1 receptor ("TRPA1") antagonist and a glucocorticoid.
摘要翻译： 本专利申请涉及包含瞬时受体电位锚蛋白-1受体（“TRPA1”）拮抗剂和糖皮质激素的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.035 秒)
